Labetalol: Mixed Alpha/Beta Blockade, Severe Hypertension and Obstetric Safety

Evidence-informed pharmacology monograph. Updated 10 November 2026. For education; drug selection and administration require current local labeling, relevant protocols and patient-specific evaluation.

Overview and mechanism

Labetalol is a mixed adrenergic antagonist with nonselective beta-1/beta-2 and alpha-1 blocking activity. Beta blockade slows rate, AV conduction and renin secretion, while alpha-1 blockade reduces peripheral resistance. Compared with a pure vasodilator, beta blockade limits reflex tachycardia; however, labetalol can still cause marked hypotension or bradycardia and is not a safer alternative for people in whom nonselective beta blockade is contraindicated [1,2].

Oral and intravenous uses

Oral labetalol treats hypertension; IV labetalol is used for selected cases of severe hypertension requiring monitored reduction. In obstetric care, IV labetalol is among accepted first-line medications for severe-range hypertension in pregnancy and postpartum under local protocols, along with other agents such as hydralazine or immediate-release nifedipine. Do not assume every hypertensive emergency has an identical BP goal or that ordinary outpatient elevated BP needs IV medication [1,3].

Mechanism-linked effects and pharmacokinetics

Labetalol has substantial hepatic first-pass metabolism and undergoes glucuronidation; oral and IV exposure and dosing schedules differ. Alpha-1 inhibition increases risk of postural hypotension, especially early or with standing after IV treatment. Beta blockade can suppress tachycardia, produce bronchospasm or aggravate some conduction abnormalities. Monitoring includes pulse, BP, respiratory status and perfusion [1,2].

Contraindications and cardiovascular precautions

The US IV label contraindicates labetalol in bronchial asthma, overt cardiac failure, heart block above first degree, cardiogenic shock and severe bradycardia. The original example suggesting it for a hypertensive patient with asthma was therefore unsafe. Avoid reflexive use in acute severe aortic stenosis or unstable bradyarrhythmias without specialist review. Beta blockers can mask hypoglycemia symptoms and oppose beta-agonist rescue bronchodilation [2].

Adverse reactions and liver injury

Dizziness, nausea, symptomatic postural hypotension, bradycardia, fatigue and bronchospasm can occur. Rare but severe hepatocellular injury and even liver failure have been reported; unexplained fatigue, abdominal symptoms, dark urine or jaundice warrant liver assessment and stopping the drug when indicated. When therapy has been established, abrupt withdrawal can aggravate coronary ischemia in susceptible patients [2].

Interactions and clinical decision-making

Combined use with other BP-lowering agents or anesthetics can potentiate hypotension; verapamil/diltiazem and other bradycardic drugs increase conduction risk. Epinephrine effects may be altered by combined alpha/beta blockade. IV use belongs in monitored settings, with underlying emergency diagnosis and pregnancy status governing choice [1–3].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. DailyMed. Labetalol hydrochloride injection: US prescribing information, revised October 2025. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbf1e4c7-7c0c-4f2f-8cad-96bc6b800cfc
  3. American College of Obstetricians and Gynecologists. Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Committee Opinion No. 767. Obstet Gynecol. 2019;133:e174–e180. Available from: https://pubmed.ncbi.nlm.nih.gov/30575639/
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *